Russian watchdog slams cartels in domestic drug market

15 May 2017

The ever increasing prices for drugs in Russia could be explained by the existing cartels, which have been created in the domestic pharmaceutical market by some global drugmakers and their distributors, according to recent statements of Igor Artemiev, head of the Russian Federal Antimonopoly Service (FAS).

Mr Artemiev said that prices for drugs that contain the same substances, but are sold in Russia under different brands in some cases, are overestimated by 160 times, reports The Pharma Letter’s local correspondent.

Mr Artemiev has also said that there are "thousands of cartels" on the Russian pharmaceutical market, pointing out that the majority of tenders in this field are conducted with serious violations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK